Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Furmonertinib mesylate by Arrivent Biopharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Furmonertinib mesylate is under clinical development by Arrivent Biopharma and currently in Phase III for Non-Small Cell Lung Cancer. According...
Data Insights
Furmonertinib mesylate by Shanghai Allist Pharmaceuticals for Lung Adenocarcinoma: Likelihood of Approval
Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma. According to...